Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.

Veronica Olivo PimentelDamiënne MarcusAlexander Ma van der WielNatasja G LieuwesRianne BiemansRelinde I Y LieverseDario NeriJan TheysAla YarominaLudwig J DuboisPhilippe Lambin

Published in: Journal for immunotherapy of cancer (2021)

This study demonstrated that combinatorial strategies rationally designed on biological effects can turn immunotherapy-resistant tumors into immunologically responsive tumors. This hypothesis is currently being tested in the international multicentric randomized phase 2 trial: ImmunoSABR (NCT03705403).

Keyphrases

early stage
radiation therapy
open label
randomized controlled trial
cancer therapy
radiation induced
clinical trial
squamous cell carcinoma
drug delivery